Biological Characterization of iPSCs and Its Applications
DOI:
https://doi.org/10.62051/ptr6rb77Keywords:
IPSCs, disease modeling, drug screening, immunotherapy.Abstract
Induced pluripotent stem cells (iPSCs) are pluripotent stem cells obtained by reprogramming somatic cells with transcription factors (e.g., OCT4, SOX2, KLF4, c-Myc), and have self-renewal and differentiation potentials similar to embryonic stem cells (ESCs). Their pluripotency allows differentiation into various cell types, maintained by core transcription factors and regulated by signaling pathways. Different species' iPSCs need specific culture conditions. iPSCs can self - renew through certain pathways, useful in high-throughput screening. They have low immunogenicity due to mechanisms like low MHC expression. Their epigenetic plasticity shows in reprogramming and differentiation. Also, iPSCs are gene-editing compatible, enabling correction of genetic diseases. In this paper, we will present the current research results of iPSCs and the future challenges of iPSCs by describing their biological properties and their corresponding applications.
Downloads
References
[1] Pang H S, Ding H Y, Zheng H. Research on patents analysis of induced pluripotent stem cell. Science Focus, 2014, 9(06): 11-23.
[2] Kang L, Chen J Y, Gao S R. Historical review of reprogramming and pluripotent stem cell research in China. Hereditas(Beijing), 2018, 40(10): 825-840.
[3] Tu X S. Stem cell transplantation for human diseases: current status and advances in basic research. Chinese Journal of Tissue Engineering Research, 2014, 18(45): 7364.
[4] Cheng Z, Guo D, Ruzi A, et al. Modeling MEN1 with patient-origin iPSCs reveals GLP-1R mediated hypersecretion of insulin. Cells, 2022, 11(15): 2387. DOI: https://doi.org/10.3390/cells11152387
[5] Liang S Z, Lin M, Chen J B, et al. Generation of multiple endocrine neoplasia 1 patient-specific induced pluripotent stem cells from blood cell. Journal of Modern Oncology, 2017, 14: 2219-2222.
[6] Dong Y B, Wang J, Zheng M Z, et al. Research progress in organoids and applications. Chinese Journal of Pharmacology and Toxicology, 2019, 33(2): 152-160.
[7] Feinberg A P, Levchenko A. Epigenetics as a mediator of plasticity in cancer. Science, 2023, 379: eaaw3835. DOI: https://doi.org/10.1126/science.aaw3835
[8] Li M, Belmonte J C I. Looking to the future following 10 years of induced pluripotent stem cell technologies. Nature Protocols, 2016, 11(9): 1579-1585. DOI: https://doi.org/10.1038/nprot.2016.108
[9] Wang H Y, Yang X F, Hu C F, et al. CRISPR/Cas9 gene editing in diabetes cell therapy: recent advances. Chinese Bulletin of Life Sciences, 2019, 31(07): 723-730.
[10] Vlassis A, Jensen T L, Mohr M, et al. CRISPR-Cas12a-integrated transgenes in genomic safe harbors retain high expression in human hematopoietic iPSC-derived lineages and primary cells. iScience, 2023, 26(12): 108287. DOI: https://doi.org/10.1016/j.isci.2023.108287
[11] Bao L W, Zhou Y Y, Zeng F Y. Advances in gene therapy for β-thalassemia and hemophilia based on the CRISPR/Cas9 technology. Hereditas(Beijing), 2020, 42(10): 949-964.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Transactions on Materials, Biotechnology and Life Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
